glp-1 agonist clinical trials Cardiovascular outcomes in major with receptor agonists Obesity Clinical Trials | Expert

A deeper insight into how the diverse hallmarks of aging contribute hierarchically in different organs offers a clear foundation for combination therapies aimed at various biological pathways involved in the decline of specific tissues

16 Joint & Musculoskeletal Pain Overweight and obesity have a profound impact on overall physical function, musculoskeletal pain and both the development and progression of osteoarthritis

At steady state, the peak-to-trough ratio (Cmax/Ctrough) is moderate, meaning that orforglipron plasma concentrations remain within a relatively narrow range between doses

Defining and characterizing the progression of type 2 diabetes

Bit of Background These new classes of antiobesity medications (ie, the GLP-1 agonists and dual agonists), referred to in this article as weight management medications, arent really new.1-4 The basic science and pharmaceutical research and development to bring these to market began more than two decades ago when two scientists, Matthias Tschop, MD, and Richard DiMarchi, PhD, hypothesized that the actions of various gut hormones may offer safe and unprecedented weight loss

Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome